Terry L. Ng

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.3K citations · Full text

Advanced Lung Cancer, Cancer Immunosurveillance, Medicine +12

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Megan M. Tu, Francis Y. F. Lee, Robert T. Jones et al. · Science Advances · 2019 · 124 citations · Full text

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre

Iryna Kuchuk, Brian Hutton, Patrícia Moretto et al. · Journal of bone oncology · 2013 · 118 citations · Full text

Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

Terry L. Ng, Brian Hutton, Mark Clemons · The Oncologist · 2015 · 90 citations · Full text

Oncology, Chemotherapy-induced Nausea, Symptomatic Treatment +10

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Terry L. Ng, Yiwei Liu, Anastasios Dimou et al. · Cancer · 2018 · 79 citations · Full text